General Information of Drug (ID: DM7A8TW)

Drug Name
Ezetimibe Drug Info
Synonyms
Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
Indication
Disease Entry ICD 11 Status REF
Atherosclerosis BD40 Approved [1]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [1]
Hyperlipidemia, familial combined, LPL related Approved [1]
Non-alcoholic fatty liver disease DB92 Approved [1]
Type-1/2 diabetes 5A10-5A11 Approved [1]
Therapeutic Class
Anticholesteremic Agents
Cross-matching ID
PubChem CID
150311
ChEBI ID
CHEBI:49040
CAS Number
163222-33-1
TTD ID
D09LWS
VARIDT ID
DR00140
INTEDE ID
DR0677
ACDINA ID
D00262

Full List of Drug Formulations Containing This Drug

Ezetimibe 10 mg tablet
Company Formulation ID FDA Description
Cadila Healthcare; Zydus Pharmaceuticals F07820 Lactose monohydrate; Sodium lauryl sulfate; Sodium stearyl fumarate; Magnesium stearate; Crospovidone; Povidone; Cellulose, microcrystalline; Starch, pregelatinized corn
Apotex; AvKARE F07828 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Povidone; Silicon dioxide; Cellulose, microcrystalline
A-S Medication Solutions; Physicians Total Care F07831 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Povidone; Cellulose, microcrystalline
Aurobindo Pharma F07821 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Crospovidone (15 mpa.s at 5%); Hypromellose 2208 (3 mpa.s); Microcrystalline cellulose
Actavis Pharma F07822 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Crospovidone, unspecified; Hypromellose 2910 (3 mpa.s); Microcrystalline cellulose
Bryant Ranch Prepack; Sandoz F07823 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline; Hypromellose 2910 (15 mpa.s)
Golden State Medical Supply F07825 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Povidone, unspecified; Starch, corn
Ohm Laboratories F07826 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Povidones; Starch, corn
RemedyRepack F07829 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline; Povidones
A-S Medication Solutions; Prasco F07830 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Microcrystalline cellulose; Povidone, unspecified
Cardinal Health F07832 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline; Povidones
American Health Packaging; Glenmark Pharmaceutials; Par Pharmaceutical F07827 Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Povidones
Amneal Pharmaceuticals F07824 Lactose monohydrate; Magnesium stearate; Croscarmellose sodium; Povidone; Sodium laureth-12 sulfate
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Formulation(s)

References

1 Ezetimibe FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6816).